This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen with modifications based on factors including diagnosis, disease status, and prior treatment.
SparkCures ID | 803 |
---|---|
Trial Phase | Phase 2 |
Enrollment | 162 Patients |
Treatments |
|
Tags | |
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Adequate organ function is defined as:
Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View Centers